Emperra, a German start-up that has created a digital diabetes management solution consisting of smart hardware and software, has completed a Series B financing round of USD 3.1 million, with Robert Bosch Venture Capital GmbH (RBVC), a corporate venture capital company of the Bosch Group, joining the existing investors Peppermint VenturePartners and Investitionsbank des Landes Brandenburg. CEO Dr. Krey and CTO Dr. Schildt, management of Emperra, also participated in the round. The funds will be used for further product development and to accelerate international growth, predominantly in the United States and Europe.
With its flagship product ESYSTA®, Emperra has debuted the first ever fully integrated digital diabetes management system. In it, key innovations such as smart insulin pens (usable with all major insulin brands), wireless blood glucose meters, and CE-certified software work together seamlessly. The therapy data can be shared among all stakeholders (patient, physicians, nurses, care givers including relatives) and displayed via multiple channels, including a web-based portal, smart TV, and apps.
“ESYSTA® provided us with compelling evidence of medical benefit in a study involving more than 200 patients,” says Dr. Dieter Kraft, an investment partner of Robert Bosch Venture Capital GmbH. “It was shown that mean glucose levels (measured as HbA1c) were significant lowered without increasing the potentially life-threatening risk of hypoglycemia”.
In Germany, ESYSTA® has already received reimbursement status from German health insurers, which means ESYSTA hardware and software is now available on prescription for any patient with diabetes. Initial success in the German market confirms the effectiveness of this fully integrated diabetes care management.
“Digital health is poised to transform healthcare. With its data-driven therapy management, Emperra is excellently positioned to contribute to this transformation in the field of diabetes care,” says Gitte Bedford, vice president of Robert Bosch Venture Capital. “Involving high-quality investors such as Bosch demonstrates the potential in our unique approach to diabetes care,” says Dr. Christian Krey, the CEO of Emperra. “In particular, having Bosch as a strategic investor means we have access to its global expertise in software automation, connected communities, and sensor technologies.”
Dr. Klaus Stoeckemann, the co-founder and managing partner of Peppermint VenturePartner and acting chairman of the Emperra board, says: “As one of the lead investors of the Series A round, we continued to support Emperra by participating in the B round. We are pleased to add RBVC to our syndicate, and hope it will accelerate Emperra’s expansion into international markets”.
„With our first evidence of the medical benefits and a proven telemedicine approach, we have set the foundation to win RBVC as a strategic partner. As existing investor it is an excellent proof that we are on the right track with Emperra,“ said Martin Laub, member of the Emperra board and senior investment manager ILB.